Relay Therapeutics filed an 8-K on August 6, 2026, announcing the amendment to its At-the-Market (ATM) equity offering program with TD Securities. The amendment increases the aggregate offering size from $250 million to $462,978,049. Approximately $162,978,049 had already been sold under the original agreement as of the filing date. Concurrently, the company reported second-quarter 2026 financial results, reporting a net loss of $83.7 million ($0.41 per share) on revenue of $0.4 million. The company ended the quarter with $910.9 million in cash and investments, providing an expected operating runway into 2029. Relay Therapeutics is a clinical-stage biotechnology company developing precision medicine therapies for cancer and genetic diseases.

Relay Therapeutics, Inc. filed a Certificate of Second Amendment to its Fourth Amended and Restated Certificate of Incorporation on June 9, 2026, to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000. The company's stockholders' Annual Meeting held on the same date also elected Douglas S. Ingram and Claire Mazumdar, Ph.D. to class III directors. Relay Therapeutics, Inc. is a biotechnology company focused on developing protein-based therapeutics.